Barr E S & Co. decreased its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 2.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 112,230 shares of the company’s stock after selling 2,825 shares during the quarter. Johnson & Johnson accounts for 1.7% of Barr E S & Co.’s portfolio, making the stock its 19th largest position. Barr E S & Co.’s holdings in Johnson & Johnson were worth $29,712,000 at the end of the most recent quarter.
Other hedge funds also recently added to or reduced their stakes in the company. National Pension Service grew its position in shares of Johnson & Johnson by 1.3% during the second quarter. National Pension Service now owns 5,226,968 shares of the company’s stock valued at $1,327,493,000 after purchasing an additional 67,484 shares in the last quarter. IFP Advisors Inc increased its position in Johnson & Johnson by 8.8% in the second quarter. IFP Advisors Inc now owns 38,760 shares of the company’s stock worth $9,844,000 after purchasing an additional 3,133 shares during the last quarter. Elefante Mark B increased its position in Johnson & Johnson by 9.8% in the second quarter. Elefante Mark B now owns 28,686 shares of the company’s stock worth $7,285,000 after purchasing an additional 2,563 shares during the last quarter. AMG Asset Management Group Inc. raised its stake in Johnson & Johnson by 172.0% during the third quarter. AMG Asset Management Group Inc. now owns 3,852 shares of the company’s stock valued at $1,020,000 after purchasing an additional 2,436 shares in the last quarter. Finally, Gradient Investments LLC grew its stake in shares of Johnson & Johnson by 9.9% in the 2nd quarter. Gradient Investments LLC now owns 152,831 shares of the company’s stock worth $38,815,000 after buying an additional 13,737 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.
Johnson & Johnson News Roundup
Investors following JNJ have been watching these news items:
- Positive Sentiment: J&J reported favorable Phase 3 results for CAPLYTA in adults with bipolar I disorder, with the drug providing rapid relief of manic symptoms. Positive data could strengthen the case for expanding the medicine’s use and future sales. Johnson & Johnson Reports Favorable Data For Bipolar Study
- Positive Sentiment: The company is backing Francis Medical as it advances its Vanquish water-vapor therapy device for prostate cancer through the FDA premarket approval process. J&J also led a $100 million funding round for Delix Therapeutics, supporting development of psychedelic-inspired depression treatments. The deals broaden its potential reach in cancer care and psychiatry, though both carry development and regulatory risk. J&J leads Francis Medical investment to fund prostate cancer device Johnson & Johnson backs new cancer device and leads $100 million depression bet
- Negative Sentiment: Pomerantz LLP said it is investigating potential claims on behalf of J&J investors. The announcement does not establish wrongdoing or the outcome of any claims, but adds another legal headline for investors to monitor. Pomerantz law firm investigates claims on behalf of J&J investors
Johnson & Johnson Stock Up 1.2%
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.53 by $0.06. The company had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. Johnson & Johnson’s quarterly revenue was up 5.9% on a year-over-year basis. During the same period last year, the business posted $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Sell-side analysts expect that Johnson & Johnson will post 11.12 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be paid a dividend of $1.34 per share. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 annualized dividend and a dividend yield of 1.9%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 81.21%.
Wall Street Analyst Weigh In
A number of analysts have recently weighed in on the stock. Argus set a $300.00 target price on shares of Johnson & Johnson in a report on Wednesday, July 29th. Evercore set a $300.00 price objective on Johnson & Johnson in a research report on Tuesday, October 20th. Erste Group Bank lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, October 21st. The Goldman Sachs Group reissued a “buy” rating and set a $282.00 target price on shares of Johnson & Johnson in a research report on Thursday, July 16th. Finally, Wall Street Zen lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $275.92.
Read Our Latest Analysis on JNJ
Insider Activity
In related news, EVP Jennifer Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares in the company, valued at $51,210,615.36. The trade was a 7.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the transaction, the executive vice president owned 25,447 shares in the company, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 0.16% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.
See Also
- Five stocks we like better than Johnson & Johnson
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
